{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:13:07Z","timestamp":1788243187446,"version":"build-2803163510"},"reference-count":30,"publisher":"The Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"Context: Primary hyperparathyroidism (PHPT) is characterized by elevated serum calcium (Ca) and increased PTH concentrations.<\/jats:p>\n Objective: The objective of the investigation was to establish the efficacy of cinacalcet in reducing serum Ca in patients with PHPT across a wide spectrum of disease severity.<\/jats:p>\n Design and Setting: The study was a pooled analysis of data from three multicenter clinical trials of cinacalcet in PHPT.<\/jats:p>\n Patients : Patients were grouped into three disease categories for analysis based on the following: 1) history of failed parathyroidectomy (n = 29); 2) meeting one or more criteria for parathyroidectomy but without prior surgery (n = 37); and 3) mild asymptomatic PHPT without meeting criteria for either above category (n = 15).<\/jats:p>\n Intervention: The intervention in this study was treatment with cinacalcet for up to 4.5 yr.<\/jats:p>\n Outcomes: Measurements in the study included serum Ca, PTH, phosphate, and bone-specific alkaline phosphatase, and areal bone mineral density (aBMD). Vital signs, safety biochemical and hematological indices, and adverse events were monitored throughout the study period.<\/jats:p>\n Results: The extent of cinacalcet-induced serum Ca reduction, proportion of patients achieving normal serum Ca (\u226410.3 mg\/dl), reduction in serum PTH, and increase in serum phosphate were similar across all three categories. Except for decreased aBMD at the total femur indicated for parathyroidectomy group at 1 yr, no significant changes in aBMD occurred. The efficacy of cinacalcet was maintained for up to 4.5 yr of follow-up. AEs were mild and similar across the three categories.<\/jats:p>\n Conclusions: Cinacalcet is equally effective in the medical management of PHPT patients across a broad spectrum of disease severity, and overall cinacalcet is well tolerated.<\/jats:p>","DOI":"10.1210\/jc.2010-1221","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T07:04:26Z","timestamp":1287039866000},"page":"E9-E18","source":"Crossref","is-referenced-by-count":97,"title":["Cinacalcet HCl Reduces Hypercalcemia in Primary Hyperparathyroidism across a Wide Spectrum of Disease Severity"],"prefix":"10.1210","volume":"96","author":[{"given":"Munro","family":"Peacock","sequence":"first","affiliation":[{"name":"Department of Medicine (M.P.), Indiana University School of Medicine, Indianapolis, Indiana 46202"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"Department of Medicine (J.P.B.), Columbia University, College of Physicians and Surgeons, New York, New York 10032"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Bolognese","sequence":"additional","affiliation":[{"name":"Bethesda Health Research (M.A.B.), Bethesda, Maryland 20817"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borofsky","sequence":"additional","affiliation":[{"name":"Clinical Research Center of Reading (M.B.), LLP, West Reading, Pennsylvania 19611"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Scumpia","sequence":"additional","affiliation":[{"name":"Austin Thyroid and Endocrinology (S.S.), Austin, Texas 78758"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. R.","family":"Sterling","sequence":"additional","affiliation":[{"name":"Amgen, Inc. (L.R.S., S.C.), Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunfa","family":"Cheng","sequence":"additional","affiliation":[{"name":"Amgen, Inc. (L.R.S., S.C.), Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Shoback","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit (D.S.), Department of Medicine, Department of Veterans Affairs Medical Center, University of California, San Francisco, California 94121"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071615253930200_R1","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1210\/jc.2002-021370","article-title":"Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.","volume":"87","author":"Bilezikian","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1210\/jc.2008-1758","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/jc.2008-1760","article-title":"Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.","volume":"94","author":"Silverberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R4","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1210\/jc.2007-1215","article-title":"The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.","volume":"93","author":"Rubin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.","volume":"341","author":"Silverberg","year":"1999","journal-title":"N Engl J Med"},{"key":"2020071615253930200_R6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1210\/jc.2008-1761","article-title":"Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.","volume":"94","author":"Udelsman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"2020071615253930200_R7","first-page":"N87","article-title":"Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum","volume":"17","author":"Peacock","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2020071615253930200_R8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2796.2005.01600.x","article-title":"Positive effect of parathyroidectomy on bone mineral density in mild asymptomatic primary hyperparathyroidism.","volume":"259","author":"Hagstro\u0308m","year":"2006","journal-title":"J Intern Med"},{"key":"2020071615253930200_R9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF01623394","article-title":"Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report.","volume":"6","author":"Diamond","year":"1996","journal-title":"Osteoporos Int"},{"key":"2020071615253930200_R10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-125-5-199609010-00002","article-title":"The effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial.","volume":"125","author":"Grey","year":"1996","journal-title":"Ann Intern Med"},{"key":"2020071615253930200_R11","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism.","volume":"88","author":"Rubin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R12","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00007611-199606000-00020","article-title":"Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.","volume":"89","author":"Tal","year":"1996","journal-title":"South Med J"},{"key":"2020071615253930200_R14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","article-title":"Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid.","volume":"366","author":"Brown","year":"1993","journal-title":"Nature"},{"key":"2020071615253930200_R15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1043-2760(98)00119-2","article-title":"Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism.","volume":"10","author":"Nemeth","year":"1999","journal-title":"Trends Endocrinol Metab"},{"key":"2020071615253930200_R16","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R18","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.","volume":"88","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R19","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.","volume":"94","author":"Peacock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R20","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","article-title":"Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.","volume":"92","author":"Silverberg","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615253930200_R21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":"Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.","volume":"44","author":"Harris","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2020071615253930200_R22","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1093\/ndt\/gfg420","article-title":"Calcium-sensing receptor and renal cation handling.","volume":"18","author":"Houillier","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2020071615253930200_R23","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1210\/endo.140.12.7190","article-title":"Expression and signal transduction of calcium-sensing receptors in cartilage and bone.","volume":"140","author":"Chang","year":"1999","journal-title":"Endocrinology"},{"key":"2020071615253930200_R24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s004240000436","article-title":"Dietary phosphate and parathyroid hormone alter the expression of the calcium-sensing receptor (CaR) and the Na+-dependent Pi transporter (NaPi-2) in the rat proximal tubule.","volume":"441","author":"Riccardi","year":"2000","journal-title":"Pflugers Arch"},{"key":"2020071615253930200_R25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","article-title":"Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.","volume":"5","author":"Wetmore","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020071615253930200_R26","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1681\/ASN.2006070783","article-title":"Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism.","volume":"18","author":"Kawata","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2020071615253930200_R27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S8756-3282(03)00202-3","article-title":"Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure.","volume":"33","author":"Frolik","year":"2003","journal-title":"Bone"},{"key":"2020071615253930200_R28","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2020071615253930200_R29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1359\/JBMR.041204","article-title":"\u03b2-Arrestin 2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice.","volume":"20","author":"Bouxsein","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071615253930200_R30","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1210\/en.2007-0147","article-title":"Constitutive activity of the osteoblast Ca2+-sensing receptor promotes loss of cancellous bone.","volume":"148","author":"Dvorak","year":"2007","journal-title":"Endocrinology"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/1\/E9\/10745321\/jcem00E9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/1\/E9\/10745321\/jcem00E9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T02:37:12Z","timestamp":1594953432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/96\/1\/E9\/2833334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2010-1221","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,1]]}}}